Advertisement

Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers

      Abstract

      Background

      MS relapses are unpredictable and can be concerning to patients and their caregivers.

      Objective

      To assess the direct and indirect cost burden associated with relapses of different severities in MS patients and with MS relapse frequency on spouse caregivers.

      Methods

      Using a U.S. insurance claims and employee disability database (1999–2011), we studied adult MS patients (ICD-9-CM: 340.x) and their spouse caregivers. A previously published algorithm to identify relapses was used to stratify: (1) MS patients into cohorts of no, low/moderate, and high severity relapse based on the most severe relapse within one year of follow-up (if any); (2) caregivers into cohorts of no, less, and more frequent relapses based on the overall frequency of relapses of their spouse. Adjusted cost differences and 95% confidence intervals evaluating the yearly incremental costs at 12 months of follow-up (MS patients) and overall (caregivers) associated with relapses are reported.

      Results

      Among the 9421 MS patients (N: no relapse = 7686; low/moderate severity relapse = 1220; high severity relapse = 515) identified, both relapse cohorts incurred significantly higher annual incremental direct costs than the no relapse cohort (low/moderate severity = $8269 [6565–10,115]; high severity = $24,180 [20,263–28,482]) and indirect costs (low/moderate severity = $1429 [759–2147]; high severity = $2714 [1468–4035]). More frequent relapses versus no relapse also translated into a significantly greater cost burden for caregivers (direct + indirect = $1725 [376–2885]) but less frequent relapses did not.

      Conclusions

      Relapse severity was significantly and increasingly associated with greater direct and indirect costs in MS patients. More frequent relapses also translated into a significant cost burden in spouse caregivers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Keegan B.M.
        • Noseworthy J.H.
        Multiple sclerosis.
        Annu Rev Med. 2002; 53: 285-302
        • U.S. Food and Drug Administration
        First monoclonal antibody treatment for multiple sclerosis approved. P04-107.
        (Available at:) ([Accessed March 24, 2013])
        • National Multiple Sclerosis Society
        Who gets MS?.
        (Available at:) ([Accessed March 24, 2013])
        • National Institute of Neurological Disorders and Stroke
        Multiple sclerosis: hope through research.
        (Available at:) ([Accessed March 24, 2013])
        • Vollmer T.
        The natural history of relapses in multiple sclerosis.
        J Neurol Sci. 2007; 256: S5-S13
        • Weinshenker B.G.
        • Bass B.
        • Rice G.P.A.
        • Noseworthy J.
        • Carriere W.
        • Baskerville J.
        • et al.
        The natural history of multiple sclerosis: a geographically based study 2: predictive value of the early clinical course.
        Brain. 1989; 112: 1419-1428
        • Sormani M.P.
        • Li D.K.
        • Bruzzi P.
        • Stubinski B.
        • Cornelisse P.
        • Rocak S.
        • et al.
        Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
        Neurology. 2011; 77: 1684-1690
        • Lublin F.D.
        • Baier M.
        • Cutter G.
        Effect of relapses on development of residual deficit in multiple sclerosis.
        Neurology. 2003; 61: 1528-1532
        • Confavreux C.
        • Vukusic S.
        • Moreau T.
        • Adeleine P.
        Relapses and progression of disability in multiple sclerosis.
        N Engl J Med. 2000; 343: 1430-1438
        • Kremenchutzky M.
        • Rice G.P.A.
        • Baskerville J.
        • Wingerchuk D.M.
        • Ebers G.C.
        The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
        Brain. 2006; 129: 584-594
        • Whetten-Goldstein K.
        • Sloan F.A.
        • Goldstein L.B.
        • Kulas E.D.
        A comprehensive assessment of the cost of multiple sclerosis in the United States.
        Mult Scler. 1998; 4: 419-425
        • Pope G.C.
        • Urato C.J.
        • Kulas E.D.
        • Kronick R.
        • Gilmer T.
        Prevalence, expenditures, utilization, and payment for persons with MS in insured populations.
        Neurology. 2002; 58: 37-43
        • O'Brien J.A.
        • Ward A.J.
        • Patrick A.R.
        • Caro J.
        Cost of managing an episode of relapse in multiple sclerosis in the United States.
        BMC Health Serv Res. 2003; 3: 17
        • Kobelt G.
        • Berg J.
        • Atherly D.
        • Hadjimichael O.
        Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States.
        Neurology. 2006; 66: 1696-1702
        • Prescott J.D.
        • Factor S.
        • Pill M.
        • Levi G.W.
        Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
        J Manag Care Pharm. 2007; 13: 44-52
        • Patwardhan M.B.
        • Matchar D.B.
        • Samsa G.P.
        • McCrory D.C.
        • Williams R.G.
        • Li T.T.
        Cost of multiple sclerosis by level of disability: a review of literature.
        Mult Scler. 2005; 11: 232-239
        • Aronson K.J.
        Quality of life among persons with multiple sclerosis and their caregivers.
        Neurology. 1997; 48: 74-80
        • Figved N.
        • Myhr K.M.
        • Larsen J.P.
        • Aarsland D.
        Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms.
        J Neurol Neurosurg Psychiatry. 2007; 78: 1097-1102
        • Ollendorf D.A.
        • Jilinskaia E.
        • Oleen-Burkey M.
        Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population.
        J Manag Care Pharm. 2002; 8: 469-476
        • Chastek B.J.
        • Oleen-Burkey M.
        • Lopez-Bresnahan M.V.
        Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims.
        J Med Econ. 2010; 13: 618-625
        • Yamamoto D.
        • Campbell J.D.
        Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.
        Autoimmune Dis. 2012; : 784364
        • Kobelt G.
        • Lindgren P.
        • Smala A.
        • Bitdch A.
        • Haupts M.
        • Kolmel H.W.
        • et al.
        Costs and quality of life in multiple sclerosis. An observational study in Germany.
        HEPAC. 2001; 2: 60-68
        • Kobelt G.
        • Lindgren P.
        • Parkin D.
        • et al.
        Costs and quality of life in multiple sclerosis: a cross-sectional observational study in the United Kingdom.
        in: EFI Research Reports, Stockholm, Sweden. 2000
        • Henriksson F.
        • Fredrikson S.
        • Masterman T.
        • Jonsson B.
        Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden.
        Eur J Neurol. 2001; 8: 27-35
        • Grima D.T.
        • Torrance G.W.
        • Francis G.
        • Rice G.
        • Rosner A.J.
        • Lafortune L.
        Cost and health related quality of life consequences of multiple sclerosis.
        Mult Scler. 2000; 6: 91-98
        • Asche C.V.
        • Singer M.E.
        • Jhaveri M.
        • Chung H.
        • Miller A.
        All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
        J Manag Care Pharm. 2010; 16: 703-712
        • Naci H.
        • Fleurence R.
        • Birt J.
        • Duhig A.
        Economic burden of multiple sclerosis: a systematic review of the literature.
        Pharmacoeconomics. 2010; 28: 363-379
        • Ivanova J.
        • Birnbaum H.G.
        • Samuels S.
        • Davis M.
        • Phillips A.L.
        • Meletiche D.
        The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.
        Pharmacoeconomics. 2009; 27: 681-691
        • Halper J.
        The psychosocial effect of multiple sclerosis: the impact of relapses.
        J Neurol Sci. 2007; 256: S34-S38
        • Murphy N.
        • Confavreux C.
        • Haas J.
        • König N.
        • Roullet E.
        • Sailer M.
        • et al.
        Economic evaluation of multiple sclerosis in the UK, Germany, and France.
        Pharmacoeconomics. 1998; 13: 607-622
        • Amato M.P.
        • Battaglia M.A.
        • Caputo D.
        • Fattore G.
        • Gerzeli S.
        • Pitaro M.
        • et al.
        The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy.
        J Neurol. 2002; 249: 152-163